Siglec-3/CD33 Mouse anti-Human, Clone: C33/69, Novus Biologicals
Mouse Monoclonal Antibody
Manufacturer: Novus Biologicals NBP2328200.02MG
DescriptionSiglec-3/CD33 Monoclonal antibody specifically detects Antigen in Human samples. It is validated for Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry (Frozen), Immunoprecipitation.
|Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 0.5-1ug/ml, Immunoprecipitation 0.5-1ug/500ug protein lysate, Immunohistochemistry-Frozen 0.5-1ug/ml|
|CD33 antigen, CD33 antigen (gp67), CD33 molecule, FLJ00391, myeloid cell surface antigen CD33, p67, sialic acid binding Ig-like lectin 3, Sialic acid-binding Ig-like lectin 3, SIGLEC-3, SIGLEC3gp67|
|Protein A purified|
|Store at 4C.|
|Recognizes a 67kDa glycoprotein, which is identified as CD33. It is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies; these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia. CD33 is expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells. It is absent on platelets, lymphocytes, erythrocytes and hematopoietic stem cells.|
|Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Frozen)|
|PBS with 0.05% BSA. with 0.05% Sodium Azide|
|Recombinant human CD33 protein|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok